Ani pharmaceuticals, inc. ANIP.US Overview
ANIP AI Analysis & Strategy
Browsing restrictions can be lifted for a fee.
ANIP Current Performance
1.42%
Ani pharmaceuticals, inc.
1.06%
Avg of Sector
0.06%
S&P500
ANIP Key Information
ANIP Revenue by Segments
Browsing restrictions can be lifted for a fee.
ANIP Net Income
Browsing restrictions can be lifted for a fee.
ANIP Cash Flow
Browsing restrictions can be lifted for a fee.
ANIP Profit Margin
Browsing restrictions can be lifted for a fee.
ANIP PE Ratio River
Browsing restrictions can be lifted for a fee.
ANIP Financial Forecast
Browsing restrictions can be lifted for a fee.
| Quarterly | EPS Forecast | QoQ | Max | Min |
|---|---|---|---|---|
| 2025Q1 | ||||
| 2025Q2 | ||||
| 2025Q3 | ||||
| 2025Q4 | ||||
| 2026Q1 |
ANIP Earnings Table
Unit : USD
| QTR | Non-GAAP EPS | EPS YoY | EPS Surprise % | Sales | Sales YoY | Sales Surprise % | NPM |
|---|---|---|---|---|---|---|---|
| Current | |||||||
| 2024Q4 | |||||||
| 2024Q3 | |||||||
| 2024Q2 | |||||||
| 2024Q1 |
ANIP Profile
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products for other companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was incorporated in 2001 and is headquartered in Baudette, Minnesota.
Price of ANIP
ANIP FAQ
When is ANIP's latest earnings report released?
The most recent financial report for Ani pharmaceuticals, inc. (ANIP) covers the period of 2025Q1 and was published on 2025/03/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating ANIP's short-term business performance and financial health. For the latest updates on ANIP's earnings releases, visit this page regularly.
What is the operating profit of ANIP?
According to the latest financial report, Ani pharmaceuticals, inc. (ANIP) reported an Operating Profit of 14.1M with an Operating Margin of 7.15% this period, representing a decline of 30.88% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
How is ANIP's revenue growth?
In the latest financial report, Ani pharmaceuticals, inc. (ANIP) announced revenue of 197.12M, with a Year-Over-Year growth rate of 43.43%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
How much debt does ANIP have?
As of the end of the reporting period, Ani pharmaceuticals, inc. (ANIP) had total debt of 622.82M, with a debt ratio of 0.48. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.
How much cash does ANIP have?
At the end of the period, Ani pharmaceuticals, inc. (ANIP) held Total Cash and Cash Equivalents of 149.84M, accounting for 0.12 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
Does ANIP go with three margins increasing?
In the latest report, Ani pharmaceuticals, inc. (ANIP) achieved the “three margins increasing” benchmark, with a gross margin of 62.9%%, operating margin of 7.15%%, and net margin of 7.7%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess ANIP's profit trajectory and future growth potential.
Is ANIP's EPS continuing to grow?
According to the past four quarterly reports, Ani pharmaceuticals, inc. (ANIP)'s earnings per share (EPS) shows a declining trend, with the latest EPS at 0.7. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
What is the FCF of ANIP?
Ani pharmaceuticals, inc. (ANIP)'s Free Cash Flow (FCF) for the period is 32.52M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 19.54% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.
What are the PEG ratio and PE ratio of ANIP?
The latest valuation data shows Ani pharmaceuticals, inc. (ANIP) has a Price-To-Earnings (PE) ratio of -63.34 and a Price/Earnings-To-Growth (PEG) ratio of -0.09. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.